These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29781056)

  • 21. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.
    Gouda MA; Shunyakova J; Naing A; Dumbrava E; Hong DS; Yuan Y; Yang P; Myers A; Liang Y; Peng J; Karp D; Tsimberidou AM; Rodon J; Yap TA; Piha-Paul SA; Meric-Bernstam F; Fu S
    ESMO Open; 2024 Jun; 9(6):103486. PubMed ID: 38914452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Torka P; Thiruvengadam SK; Chen L; Wang X; Chen C; Vuong D; Qin H; Muir A; Orand K; Borja I; Lynne Smith D; Herrera AF; Spurgeon SEF; Park B; Lewis LD; Hernandez-Ilizaliturri F; Xia Z; Danilov AV
    Blood Cancer J; 2023 Jan; 13(1):9. PubMed ID: 36631449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
    Azad N; Perroy A; Gardner E; Imamura CK; Graves C; Sarosy GA; Minasian L; Kotz H; Raggio M; Figg WD; Kohn EC
    Cancer Biol Ther; 2009 Oct; 8(19):1800-5. PubMed ID: 19738417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
    Michael M; Vlahovic G; Khamly K; Pierce KJ; Guo F; Olszanski AJ
    Br J Cancer; 2010 Nov; 103(10):1554-61. PubMed ID: 20959830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
    Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
    Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
    Sanborn SL; Cooney MM; Dowlati A; Brell JM; Krishnamurthi S; Gibbons J; Bokar JA; Nock C; Ness A; Remick SC
    Invest New Drugs; 2008 Aug; 26(4):355-62. PubMed ID: 18470481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors.
    Seetharam M; Norman A; Allred J; Kong J; Opyrchal M; Ma WW; Lou Y; Dy GK; Mahipal A; Weroha J; Wahner-Hendrickson A; Reid JM; Adjei AA
    Res Sq; 2024 Apr; ():. PubMed ID: 38746220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
    Suh KJ; Ryu MH; Zang DY; Bae WK; Lee HS; Oh HJ; Kang M; Kim JW; Kim BJ; Mortimer PGS; Kim HJ; Lee KW
    Oncologist; 2023 Sep; 28(9):e823-e834. PubMed ID: 37036671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors.
    Abdel Karim N; Gaber O; Aljohani HM; Eldessouki I; Bahassi EM; Morris J
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3789-3796. PubMed ID: 31870123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial.
    Gatz SA; Harttrampf AC; Brard C; Bautista F; André N; Abbou S; Rubino J; Rondof W; Deloger M; Rübsam M; Marshall LV; Hübschmann D; Nebchi S; Aerts I; Thebaud E; De Carli E; Defachelles AS; Paoletti X; Godin R; Miah K; Mortimer PGS; Vassal G; Geoerger B
    Clin Cancer Res; 2024 Feb; 30(4):741-753. PubMed ID: 38051741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
    Shapiro DD; Zacharias NM; Tripathi DN; Karki M; Bertocchio JP; Soeung M; He R; Westerman ME; Gao J; Rao P; Lam TNA; Jonasch E; Perelli L; Cheng EH; Carugo A; Heffernan TP; Walker CL; Genovese G; Tannir NM; Karam JA; Msaouel P
    Clin Transl Med; 2023 May; 13(5):e1267. PubMed ID: 37226898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response.
    Diaz Y; Tundidor Y; Lopez A; Leon K
    Cancer Immunol Immunother; 2013 Mar; 62(3):455-69. PubMed ID: 22941039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
    Lampert EJ; Hays JL; Kohn EC; Annunziata CM; Minasian L; Yu M; Gordon N; Sissung TM; Chiou VL; Figg WD; Houston N; Lee JM
    Oncotarget; 2019 Apr; 10(30):2855-2868. PubMed ID: 31080557
    [No Abstract]   [Full Text] [Related]  

  • 34. A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors.
    Ghalib MH; Pulla MP; De Miguel Luken MJ; de Juan VC; Chaudhary I; Hammami MB; Vikash S; Maitra R; Martinez S; Kahatt C; Extremera S; Fudio S; Goel S
    Invest New Drugs; 2024 Aug; ():. PubMed ID: 39096398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
    Wong B; Bergeron A; Maznyi G; Ng K; Jirovec A; Birdi HK; Serrano D; Spinelli M; Thomson M; Taha Z; Alwithenani A; Chen A; Lorimer I; Vanderhyden B; Arulanandam R; Diallo JS
    Mol Ther; 2023 Nov; 31(11):3176-3192. PubMed ID: 37766429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic virus and inhibitor for NEDD8-activating enzyme pevonedistat: Promising combination for cancer therapy?
    Guo ZS
    Mol Ther; 2023 Nov; 31(11):3112-3114. PubMed ID: 37865096
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I Study of Muscadine Grape Extract for Patients With Advanced Cancer.
    Bitting RL; Tooze JA; Isom S; Petty WJ; Grant SC; Desnoyers RJ; Thomas A; Thomas CY; Alistar AT; Golden SL; Pleasant K; Chappell MC; Tallant EA; Gallagher PE; Klepin HD
    Am J Clin Oncol; 2021 Jun; 44(6):239-246. PubMed ID: 33867481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
    Burris HA; Berlin J; Arkenau T; Cote GM; Lolkema MP; Ferrer-Playan J; Kalapur A; Bolleddula J; Locatelli G; Goddemeier T; Gounaris I; de Bono J
    Br J Cancer; 2024 Apr; 130(7):1131-1140. PubMed ID: 38287179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
    Luke JJ; Fakih M; Schneider C; Chiorean EG; Bendell J; Kristeleit R; Kurzrock R; Blagden SP; Brana I; Goff LW; O'Hayer K; Geschwindt R; Smith M; Zhou F; Naing A
    Br J Cancer; 2023 Jun; 128(12):2227-2235. PubMed ID: 37087488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids.
    Dahl MJ; Lofgren KA; Haugen C; Harmon GE; Hughes SP; Cowden Dahl KD
    Front Oncol; 2024; 14():1368592. PubMed ID: 38544842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.